Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Weakness, Fatigue Can Signal Underlying Rheumatologic Disease

Simon M. Helfgott, MD  |  Issue: April 2017  |  April 17, 2017

Weakness implies a loss of function and a decline in strength, and it is challenging to confirm the absence, rather than the presence, of a symptom.

Weakness implies a loss of function and a decline in strength, and it is challenging to confirm the absence, rather than the presence, of a symptom.
VasilkovS/shutterstock.com

As clinicians, we are familiar with pain, stiffness and soreness—subjective nouns that define our métier. These helpful words serve as signposts that direct us along the path to the proper diagnosis.

Consider the young man with a stiff, sore back (a case of ankylosing spondylitis?) or the postpartum woman experiencing newly painful, stiff and sore fingers (the onset of rheumatoid arthritis)? How about your patient, the weekend warrior, old enough to have been alive when Woodstock rocked, who now describes feeling stiff and sore around their shoulders and hips (polymyalgia rheumatica, perhaps)? Rheumatologists are accustomed to parsing the meaning of these terms. We are the experts in triaging aches and pains. This is the essence of rheumatology.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

But interpreting another nebulous term, weakness, is another story. This noun is among the most vexing descriptors heard when taking a patient’s history, perhaps only matched by the imprecise epithets, feeling dizzy and feeling fatigued. Weakness implies a loss of function, a decline in strength, and it is always challenging to confirm the absence, rather than the presence, of a symptom. Skeletal muscle, unlike its neighboring tissues, the joints, tendons, ligaments and bursae, can silently endure an intense immune attack without raising a whimper. In contrast to all the other –itises, inflammatory myositis is generally a painless event that quietly transforms into a debilitating condition.

Because a steroid-induced myopathy is painless, patients are rarely aware of its stealthy development until the weakness begins to disrupt their lifestyle.

Hiding in Plain Sight

Years ago, some colleagues and I examined a handful of patients who presented with varying complaints of malaise, fatigue and a sense of feeling unwell that led their treating physicians astray. Several patients were noted to have elevated serum liver enzymes that, in combination with their descriptions of malaise and fatigue, led to a liver biopsy in one patient (with normal results) and consideration of this procedure in two others, creating even more diagnostic confusion. It was only when a couple of our astute fellows considered another potential source for these enzyme elevations, namely muscle, and measured the patients’ serum creatine kinase levels that the diagnosis of, what we later termed, occult myositis became evident.1

Idiopathic inflammatory myopathies (IIM), such as polymyositis and dermatomyositis, can arrive with little fanfare. Occasionally, a telltale reddish scaly skin eruption may be present or a wholly unwelcome coincidental paraneoplastic event may occur, but generally, these muscle disorders may simmer along quietly, at least for a while, evading detection. After the diagnosis is made and treatment initiated, other challenges may present, such as determining whether any persistent weakness is a manifestation of ongoing muscle inflammation requiring more aggressive immunosuppression or is an expected consequence of prior muscle damage.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:ConditionsOpinionRheuminationsSpeak Out Rheum Tagged with:Diagnosisfatigueillnessinflammatory myositisLupusMyopathyOsteoarthritisoutcomepatient careRheumatic DiseaserheumatologistthyroidTreatmentweakness

Related Articles

    New Tools for Myositis Diagnosis, Classification & Management

    April 15, 2019

    CHICAGO—At Hot Topics in Myositis, a session at the 2018 ACR/ARHP Annual Meeting, three experts discussed new classification criteria for idiopathic inflammatory myopathies (IIM) and offered practical primers on overlap myositis conditions and inclusion body myositis (IBM). New Myositis Classification Criteria After a 10-year development process, the new EULAR/ACR Classification Criteria for Adult and Juvenile…

    Autoantibodies in Autoimmune Myopathy

    Autoantibodies in Autoimmune Myopathy

    September 18, 2017

    In recent years, scientists and clinicians have learned a great deal about autoantibodies occurring in idiopathic inflammatory myopathies (IIMs). These new discoveries have reshaped our understanding of distinct clinical pheno­types in IIMs. Scientists continue to learn more about how these auto­antibodies shape pathophysiology, diagnosis, disease monitoring, prognosis and optimum treatment. Moving forward, these autoantibodies will…

    Case Report: Tumor Treatment Unleashes Autoimmunity

    November 17, 2019

    Immune checkpoint inhibitors (ICIs) targeting the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or programmed cell death protein 1 (PD-1) axes have revolutionized therapy and improved survival in advanced cancers. However, these immune system modulators also lead to immune-related adverse events (IRAEs).1,2 In clinical trials, IRAEs mainly involved the gastrointestinal tract, skin, endocrine glands, liver and lung,…

    Rehabilitation and Myositis

    January 1, 2008

    Physical therapy to manage inflammatory muscle disease

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences